OPKO Health stock: Piper Sandler lifts target for OPKO Health stock to USD 4.00
Piper Sandler has raised its target for OPKO Health (OPK) stock to USD 4.00 from USD 3.00, maintaining an "Overweight" rating. This adjustment follows OPKO Health's agreement to sell certain BioReference Health assets to Labcorp for USD 722 million in cash, aiming to streamline operations and focus on its biopharmaceutical business. The company is expected to report its third-quarter results on October 28, 2026.
Greenberg Traurig Advises OPKO Health on $722M+ Agreement to Sell Select BioReference Health Assets to Labcorp
Greenberg Traurig, P.A. advised OPKO Health, Inc. on its agreement to sell select assets of its subsidiary, BioReference Health, LLC, to Labcorp for $722 million in cash at closing, with an potential additional $150 million earnout based on 4Kscore® Test revenue. The transaction involves Labcorp acquiring BioReference Health's clinical and women's health testing services, urology, corrections businesses, and operational assets. The deal team for Greenberg Traurig was led by Miami Corporate Practice Co-Chair Drew M. Altman and Shareholder Guillaume Le Masson, with significant contributions from other shareholders and associates across various practices.
H.C. Wainwright keeps USD 3.00 target for OPKO Health stock
H.C. Wainwright has reiterated a Buy rating and a USD 3.00 price target for OPKO Health, based on the company's Q2 2026 revenue of USD 163.60 million, which exceeded analyst forecasts. Despite reporting an adjusted loss, the pharmaceutical and diagnostics company showed a 4.30% year-over-year revenue increase. The stock's valuation is heavily reliant on future earnings improvement, with its market capitalization at USD 1.3 billion and a negative trailing P/E.
Barrington sets USD 2.25 target for OPKO Health stock
Barrington Research has set a target price of USD 2.25 for OPKO Health (OPK) stock, upgrading it from Market Perform to Outperform. This target is 47.06 percent higher than the stock's closing price of USD 1.53 on October 16, 2026. The upgrade comes as OPKO Health reported a 4.30 percent increase in revenue to USD 163.58 million in the second quarter of 2026, though the company still posted a net loss.
OPKO Health to Sell Select BioReference Assets to Labcorp for $722M
OPKO Health announced an agreement to sell select BioReference Health assets to Labcorp for $722 million in cash, plus an earnout of up to $150 million tied to the 4Kscore Test revenues. This divestiture will allow OPKO Health to focus on its biopharmaceutical business and leverage Labcorp's scale to expand access to the 4Kscore Test. The news led to a significant increase in OPK stock, highlighting the strategic benefits of simplifying its business structure and gaining financial flexibility.
Opko Health Inc. (OPK) Stock Price | Live Quotes & Charts | NASDAQ
This page provides live quotes and charts for Opko Health Inc. (OPK) stock on NASDAQ, showing a current price of $1.55, up $0.02 (1.31%). The article also mentions that earnings information is not currently available and does not include analyst ratings or an average price target. The content primarily focuses on stock performance data and general information about the company.
OPKO Health (NASDAQ:OPK) Hits New 12-Month High Following Analyst Upgrade
OPKO Health (NASDAQ:OPK) reached a new 52-week high after Barrington Research upgraded its stock to "Outperform" with a $2.25 price target. This upgrade follows news of Labcorp's agreement to acquire select BioReference Health assets for up to $872 million, a move expected to strengthen OPKO's balance sheet and shift its focus to biopharmaceuticals. Analyst sentiment is generally positive, with a "Moderate Buy" consensus rating and a $1.93 average price target.
Opko Health stock hits 52-week high at 1.75 USD
Opko Health's stock reached a new 52-week high of $1.75 USD, trading at $1.76 USD with a market capitalization of $1.29 billion. This surge follows a 17% gain over the past week and a 33% increase over six months, though InvestingPro suggests the stock might be overvalued. Recent positive news for the company includes exceeding Q2 2026 revenue projections and an agreement for Labcorp to acquire select BioReference Health assets for $722 million.
OPKO Health (NASDAQ:OPK) Stock Rating Raised to Outperform at Barrington Research
Barrington Research has upgraded OPKO Health (NASDAQ:OPK) from "market perform" to "outperform," setting a $2.25 price target, indicating a 39.75% upside. This upgrade follows OPKO's recent quarterly earnings that surpassed expectations and news of Labcorp's potential acquisition of BioReference assets, which could strengthen OPKO's balance sheet and allow for a greater focus on its biopharmaceutical pipeline. Analyst sentiment for OPKO Health is generally positive, with a "Moderate Buy" consensus rating.
OPKO HEALTH, INC. : BARRINGTON RESEARCH RAISES TO OUTPERFORM FROM MARKET PERFORM
Barrington Research has upgraded its rating for OPKO Health, Inc. from Market Perform to Outperform. This signals a more positive outlook on the company's stock performance from the research firm.
Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health
Labcorp has announced an agreement with OPKO Health to acquire select assets of BioReference Health for $722 million in cash, with a potential earnout of up to $150 million. This acquisition will expand Labcorp's clinical laboratory services, including women's health, urology, and corrections testing, and will make BioReference Health's FDA-approved 4Kscore® Test more broadly available. The transaction aims to strengthen Labcorp's specialized diagnostic services while allowing OPKO Health to focus on its biopharmaceutical business.
OPKO Health (NASDAQ:OPK) Shares Gap Up - What's Next?
OPKO Health (NASDAQ:OPK) shares gapped up significantly, opening at $1.65 after closing at $1.37, with heavy trading volume. Despite exceeding quarterly expectations with a loss of $0.01 per share and increased revenue, the company remains unprofitable. Analyst ratings are mixed, resulting in a consensus "Hold" rating with an average price target of $1.55.
Labcorp to Acquire Certain Assets of OPKO Health's BioReference Health Subsidiary for $722 Million
Labcorp has announced an agreement to acquire certain assets from OPKO Health's BioReference Health subsidiary for $722 million. The article indicates this is a premium news item from MT Newswires, requiring a subscription to read the full details. Stock symbols LH and OPK are mentioned with their respective percentage changes.
OPK Stock Grinds Lower As Traders Focus On Cash And Charts
Opko Health Inc. (OPK) stock has been slipping despite strong gross margins and a significant cash reserve, indicating persistent selling pressure. While premarket volatility offers short-term trading opportunities, the stock struggles to sustain upward momentum due to negative profit margins and cash flow. Traders are closely watching price action and fundamental improvements to determine future direction.
OPK Stock Slips As Traders Weigh Weak Margins And Support Levels
Opko Health Inc. (OPK) stock has seen a significant slip from late-September highs, signaling selling pressure despite a 15.33% intraday gain. The company, while showing strong gross margins, is grappling with negative EBIT and profit margins, indicating it's still burning cash. Traders are closely watching the $1.30–$1.40 range as a critical support level for potential technical trades.
OPK Stock Slides As Charts Flash Potential Pivot Zone
Opko Health Inc. (OPK) stock has seen a significant slide from late-September highs despite a 21.09% intraday jump, showing increasing short-term volatility. The company faces financial challenges with negative margins and ongoing losses, though a strong gross margin and solid liquidity provide some runway. Traders are closely watching support levels and intraday price action, characterized by sharp premarket spikes followed by selling, as the stock sits at a critical technical crossroads for its year-end trend.
Opko Health stock soars on $722M BioReference asset sale
Opko Health Inc. (NASDAQ:OPK) shares surged by 20% in premarket trading after Labcorp Holdings Inc. (NYSE:LH) agreed to acquire select assets of BioReference Health for $722 million in cash. The deal includes BioReference Health's laboratory testing businesses, certain operational assets, and the proprietary 4Kscore Test. This transaction will allow OPKO to streamline operations and focus on its biopharmaceutical business, while Labcorp expects the acquired business to generate approximately $250 million in revenue in the first year.
A prostate cancer blood test may reach more patients if Labcorp completes its deal
Labcorp has agreed to acquire select assets of BioReference Health from OPKO Health for $722 million in cash, with a potential earnout of up to $150 million based on 4Kscore Test revenue. This acquisition includes BioReference's clinical, women's health, urology, and corrections testing businesses, along with over 80 patient service centers and the FDA-approved 4Kscore Test for aggressive prostate cancer. The deal is expected to expand access to Labcorp's diagnostic services and allow OPKO to focus on its biopharmaceutical business.
OPKO Health Q3 2026 Earnings Date and Estimates
OPKO Health (NASDAQ:OPK) is projected to release its Q3 2026 earnings after market close on Wednesday, November 4, 2026. Analysts anticipate the company will report a loss of -$0.07 per share on revenues of $136.62 million. The earnings conference call is scheduled for October 28, 2026, at 4:30 PM ET.
OPKO Health stock triggers USD 121 million note conversions
OPKO Health (OPK) has triggered the conversion of $121 million in 3.75% convertible senior notes due 2029, as its stock price closed above the required threshold. The company's Q2 2026 revenue increased by 4.3% year-over-year to $163.58 million, and its adjusted loss per share improved significantly. Despite ongoing losses, analysts maintain a consensus "Hold" rating with an average 12-month price target close to the current stock price.
OPKO shares convertible after stock climbs above trigger; $121M notes convertible into equity
OPKO Health's 3.75% Convertible Senior Notes due 2029, totaling approximately $121 million, have become convertible into common stock. This conversion was triggered because the company's stock closed above $1.495 (130% of its $1.15 conversion price) for 20 out of 30 trading days. Holders converting will receive 869.5652 shares per $1,000 principal, plus any additional shares under early conversion terms, and OPKO will satisfy these conversions with common stock.
Here's Why You Should Retain OPK Stock in Your Portfolio for Now
OPKO Health, Inc. (OPK) is poised for growth due to its strong pharmaceutical portfolio, particularly RAYALDEE, strategic partnerships, and the restructuring of its BioReference diagnostics business. While pipeline developments and non-dilutive financing offer additional upside, the company faces challenges including over-reliance on RAYALDEE, early-stage clinical development risks, and uncertainties regarding 4Kscore adoption and reimbursement. Despite these concerns, analysts are maintaining a stable outlook for the stock.
795,716 Shares in OPKO Health, Inc. $OPK Bought by Bank of America Corp DE
Bank of America Corp DE recently acquired 795,716 shares of OPKO Health, Inc. (NASDAQ:OPK) during the second quarter, a stake valued at approximately $1.19 million, representing about 0.11% of the company. Institutional investors now collectively own 64.63% of OPKO Health, with other significant acquisitions made by BlackRock Inc., AWM Investment Company Inc., and Bank of New York Mellon Corp. Analysts hold a mixed sentiment on OPKO, with a consensus "Hold" rating and a target price of $1.55, following the company exceeding its Q2 earnings expectations.
OPK4048118 Bond Profile: Coupon and Redemption
This article provides a detailed profile of the OPK4048118 corporate bond issued by OPKO Health, Inc. It outlines key bond details such as issuer information, issue and maturity dates, face value, and minimum denomination. The profile also covers coupon payment specifics, including the 3.00% fixed rate, semi-annual frequency, and upcoming payout schedule, alongside redemption information.
OPK4020628 Bond Profile: Coupon and Redemption
This article provides a detailed profile of the OPK4020628 bond issued by OPKO Health, Inc., outlining its key facts, coupon payments, and redemption information. It covers issuer details, issue and maturity dates, face value, and upcoming coupon payout schedules. The bond is a fixed-rate, semi-annual coupon bond with a 3.00% interest rate, maturing in 2033.
OPKO Health, Inc. (OPK) stock price, news, quote and history
OPKO Health, Inc. (OPK) is trading at $1.62, down 0.61% as of September 29. The company operates in Pharmaceuticals and Diagnostics, with a market capitalization of $1.209 billion. Analysts have an average target price of $4.38 for OPK stock.
OPK5991654 Bond Profile: Coupon and Redemption
This article provides a detailed profile of the OPK5991654 bond issued by OPKO Health, Inc. It covers key facts about the bond, including its issuer, issue and maturity dates, face value, and minimum denomination. The profile also details the bond's interest payment schedule, outlining upcoming semi-annual coupon payouts.
OPKO Health, Inc. (OPK) stock price, news, quote and history
This Yahoo Finance article provides a comprehensive overview of OPKO Health, Inc. (OPK), including its current stock price, recent performance, financial data, and analyst insights. It details the company's operations in pharmaceutical and diagnostics segments, highlighting key drug developments and services. The article also presents performance metrics against the S&P 500 and various financial ratios.
Opko Health stock hits 52-week high at 1.74 USD
Opko Health (OPK) stock has reached a new 52-week high of $1.74 USD, reflecting a 19.44% increase over the last year and over 50% in the past six months. Despite this strong performance, InvestingPro analysis suggests the stock is currently overvalued. The company recently reported strong Q2 2026 financial results, with total revenue of $163.6 million, exceeding forecasts, and a smaller-than-expected loss per share, leading H.C. Wainwright to reiterate a Buy rating.
OPKO Health (NASDAQ:OPK) Shares Pass Above 50-Day Moving Average - Should You Sell?
OPKO Health (NASDAQ:OPK) shares have moved above their 50-day moving average, trading at $1.67 with a volume of over 5.3 million shares. Despite beating quarterly earnings expectations by reporting a narrower loss and higher revenue, the company remains unprofitable with a negative net margin. Analyst ratings are mixed, with an overall "Hold" consensus and an average price target of $1.55.
OPKO Health Pivots to Therapeutics, Eyes Data-Rich 12 to 18 Months
OPKO Health is strategically shifting its focus towards therapeutics, integrating ModeX Therapeutics, and advancing a pipeline of clinical programs in areas like obesity, growth hormone disorders, and oncology. The company is also streamlining its BioReference diagnostics business. With substantial cash reserves and external collaborations, OPKO anticipates a period of significant data releases and potential catalysts over the next 12 to 18 months, including updates on ModeX candidates, Merck's Epstein-Barr virus vaccine, and a BARDA-funded COVID antibody program.
Bank of New York Mellon Corp Takes Position in OPKO Health, Inc. $OPK
Bank of New York Mellon Corp has acquired a new position in OPKO Health, Inc. (NASDAQ:OPK), purchasing 1.33 million shares valued at approximately $2.0 million, giving them a 0.18% stake. Other institutional investors also increased their holdings in OPKO Health, with a total of 64.63% of the stock owned by hedge funds and institutional investors. Despite mixed analyst ratings, OPKO Health recently surpassed quarterly earnings estimates, reporting an adjusted loss of $0.01 per share and revenue of $163.58 million, exceeding expectations.
A healthcare conference will feature two OPKO executives on Sept. 10
OPKO Health (OPK) announced that President Elias A. Zerhouni, M.D., and Senior Vice President and CFO Adam Logal will participate in the Wells Fargo 21st Annual Healthcare Conference on September 10, 2026. They will join a fireside chat, which will be accessible via a live webcast and replay on OPKO's investor relations website. The announcement led to a 3.05% drop in OPK's stock price on September 8, 2026.
OPKO Health to Participate in the Wells Fargo 21st Annual Healthcare Conference
OPKO Health, Inc. announced that its President and Vice Chairman, Elias A. Zerhouni, M.D., and Senior Vice President and CFO, Adam Logal, will participate in the Wells Fargo 21st Annual Healthcare Conference. They will be featured in a fireside chat on Thursday, September 10, 2026, at 9:30 a.m. ET, which will be accessible via webcast and replay on the company's IR website.
OPKO Health to Participate in the Wells Fargo 21st Annual Healthcare Conference
OPKO Health, Inc. announced its participation in the Wells Fargo 21st Annual Healthcare Conference. Elias A. Zerhouni, M.D., and Adam Logal will represent the company, with a fireside chat scheduled for September 10, 2026, at 9:30 a.m. ET. A webcast of the event will be available on OPKO's IR website.
OPKO Health, Inc. (NASDAQ:OPK) Given Consensus Rating of "Hold" by Brokerages
OPKO Health, Inc. (NASDAQ:OPK) has received a consensus "Hold" rating from five brokerages, with an average 12-month price target of $1.55. The company recently reported a quarterly loss of $0.01 per share, beating analyst expectations, and revenue of $163.58 million, which was up 4.3% year-over-year and also exceeded estimates. Institutional investors and hedge funds collectively own 64.63% of OPKO's stock.
AWM Investment Company Inc. Makes New Investment in OPKO Health, Inc. $OPK
AWM Investment Company Inc. recently acquired a new stake of 2,110,000 shares in OPKO Health, Inc. (NASDAQ:OPK), valued at approximately $3,165,000. This investment makes AWM Investment Company Inc. an owner of about 0.28% of OPKO Health. Other institutional investors also made new investments in OPKO Health, and the company has received a consensus "Hold" rating from analysts with a target price of $1.55.
OPKO Health (OPK) Upgraded to Buy: Here's What You Should Know
OPKO Health (OPK) has been upgraded to a Zacks Rank #2 (Buy) due to an upward trend in earnings estimates. This upgrade suggests a positive outlook for the company's earnings, which historically correlates strongly with stock price movements. The Zacks Rank system, which uses earnings estimate revisions, aims to identify stocks with the potential for market-beating returns.
OPK Climbs 12.4% in the Past Month: Can the Stock Rally Keep Going?
OPKO Health, Inc. (OPK) shares have risen 12.4% in the last month, driven by narrower operating losses, improved margins, and favorable estimate revisions. While the company remains unprofitable, its future upside depends on clinical pipeline execution and progress at BioReference. Despite a mixed broader outlook, OPK's recent momentum is supported by its strong Momentum Score, though other style scores are less favorable.
OPK Raises $125 Million Against Royalties: What Investors Should Know
OPKO Health (OPK) has secured an additional $125 million in financing by leveraging future royalties from its mazdutide license agreement with Eli Lilly and Company (LLY). This non-dilutive funding, structured as senior secured notes maturing in 2044, provides capital for OPK's extensive clinical pipeline and operating needs without issuing new equity. While it offers immediate liquidity, the company retains exposure to future royalty growth in China, but still faces execution risks associated with its pipeline and diagnostics business.
OPK Climbs 12.4% in the Past Month: Can the Stock Rally Keep Going?
OPKO Health (OPK) shares have risen 12.4% over the past month, driven by narrower operating losses, improved margins, and favorable estimate revisions. While the company remains loss-making, its BioReference division has turned profitable, and pharmaceutical revenues have significantly increased. Upcoming clinical milestones for ModeX and other candidates in late 2026 or early 2027 could further support the stock, though profitability and execution risks remain.
OPK Raises $125 Million Against Royalties: What Investors Should Know
OPKO Health (OPK) secured an additional $125 million in non-dilutive financing against royalties from its mazdutide license agreement with Eli Lilly and Company. This funding, from HealthCare Royalty, a KKR business, provides capital without issuing common shares and helps support OPK's broad clinical pipeline, including various R&D programs. While enhancing financial flexibility, the article notes that execution risks remain for OPK's pipeline and diagnostics business, despite an improved Momentum Score.
OPKO Health Secures $125 Million Financing Against Mazdutide Royalties
OPKO Health has secured an additional $125 million in financing from HealthCare Royalty (HCRx) by leveraging its royalty interests from the mazdutide license agreement with Eli Lilly. This non-dilutive capital injection aims to enhance OPKO's financial flexibility and liquidity, allowing it to fund operations and advance its pipeline while retaining long-term upside in mazdutide royalties after a 1.5x cap on funded payments. The deal underscores the value of OPKO's royalty portfolio, particularly mazdutide's growth potential in China, and follows a strong Q2 2026 performance with narrower losses and increased revenues.
OPKO Health Secures $125 Million Financing Against Mazdutide Royalties
OPKO Health has secured an additional $125 million in financing from HealthCare Royalty (HCRx) by issuing senior secured notes backed by future royalties from its mazdutide licensing agreement with Eli Lilly. This non-dilutive capital injection allows OPKO to strengthen its financial flexibility and fund operations, while retaining long-term participation in mazdutide's royalty potential after payments reach 1.5 times the funded amount. The financing highlights the attractiveness of OPKO's royalty assets, especially given mazdutide's growth prospects in the Chinese market.
Should OPKO Health’s Royalty-Backed US$125 Million Financing Shift Matter to OPKO Health (OPK) Investors?
OPKO Health recently secured a US$125 million royalty-backed financing deal, converting future mazdutide license royalties into immediate non-dilutive capital with a 1.5-times cap on total payments. This financing aims to boost near-term liquidity without share dilution, but the company still faces significant challenges from persistent losses and increasing competition in GLP-1 and diagnostics markets. Investors are left to weigh whether existing products and partnerships can sufficiently narrow losses to justify increased debt and ongoing share buybacks.
OPKO Health (OPK) Raises $125 Million, Is The Upside Already Priced In?
OPKO Health (OPK) secured an additional $125 million in senior secured notes from HealthCare Royalty, linked to mazdutide royalties, providing non-dilutive capital. While recent share price performance shows near-term momentum, its 5-year total shareholder return has declined significantly. The article discusses two contrasting views on OPKO's valuation: a "most popular narrative" suggesting it is 68.5% undervalued with a fair value of $4.38 based on future growth and partnerships, and "another view" highlighting current overvaluation based on P/S ratio compared to the industry and its fair ratio.
OPKO Health Raises $125 Million in Additional Royalty-Backed Notes Under Amended HCR Agreement
OPKO Health has secured an additional $125 million in senior secured notes by amending its 2024 Note Purchase Agreement with HCR Injection SPV to enhance liquidity. These royalty-backed notes mature in 2044 and bear interest based on 3-month SOFR plus 7.5%, with payments primarily sourced from EirGen's profit share from Pfizer and secondarily from mazdutide sales royalties. The agreement details include guarantees from OPKO subsidiaries and security through related royalty and profit share streams.
OPKO Health (NASDAQ:OPK) Trading Down 5.4% - Here's What Happened
OPKO Health (NASDAQ:OPK) shares experienced a 5.4% drop in mid-day trading, closing at $1.325 with significantly lower trading volume than average. Despite the stock decline, the company recently reported better-than-expected quarterly earnings, with an adjusted loss of $0.01 per share against an anticipated $0.08 loss, and revenue of $163.58 million, surpassing analyst estimates. Analysts currently maintain a "Hold" consensus rating for OPKO Health, with an average price target of $1.55.
OPKO Health, Inc. (NASDAQ:OPK) Given Consensus Rating of "Hold" by Analysts
OPKO Health, Inc. (NASDAQ:OPK) has received a consensus "Hold" rating from analysts, with an average 12-month price target of $1.55. Recent analyst actions include upgrades from Weiss Ratings and Wall Street Zen, a downgrade from Barrington Research, and a reissued "buy" rating from HC Wainwright. The company recently reported Q2 earnings of ($0.01) per share, beating consensus estimates, and saw its revenue increase by 4.3% year-over-year.
OPKO Health, Inc. announced that it has received $375 million in funding from Healthcare Royalty Management, LLC
OPKO Health, Inc. has secured $375 million in funding from Healthcare Royalty Management, LLC. This includes an additional $125 million notes issuance on August 13, 2026, building on a previous strategic relationship. These notes mature in 2044 and bear interest at a variable rate with a 4.0% per annum floor, secured by royalty payments from Mazdutide.
